Preliminary data suggest that c-Kit inhibitors, including dasatinib, are highly active in c-Kit mutant melanoma (Lutzky et al, 2008; Carvajal et al, 2009, 2011; Woodman et al, 2009; Handolias et al, 2010; Guo et al, 2011), and dasatinib is currently in phase II testing in patients with solar, mucosal, and acral melanoma (‘Dasatinib in Advanced Mucosal, Acral, or Solar Melanoma,’ ClinicalTrials.gov, no date). This evidence concerns the gene KIT and melanoma.